tbuckley/cabot-search huggingface dataset:
Sustained, complete response to pexidartinib in a patient with <scp><i>CSF1R</i></scp>‐mutated Erdheim–Chester disease
Authors: Jithma P. Abeykoon, Terra L. Lasho, Surendra Dasari, Karen L. Rech, Wasantha K. Ranatunga, Michelle K. Manske, Alexander Tischer, Aishwarya Ravindran, Jason R. Young, William Oliver Tobin, Eoin P. Flanagan, Kevin E. Nowakowski, Gordon J. Ruan, Mithun V. Shah, Nabila Nora Bennani, Robert Vassallo, Jay H. Ryu, Matthew J. Koster, Caroline J. Davidge‐Pitts, Mrinal M. Patnaik, Xiaosheng Wu, Thomas E. Witzig, Gaurav Goyal, Ronald S. Go
Journal: American Journal of Hematology (2022)

Abstract Erdheim–Chester disease (ECD) is a histiocytic neoplasm that predominantly harbors mitogen‐activated protein kinase (MAPK) pathway variants. MAPK inhibitors typically are effective treatments, but mutations outside the MAPK pathway, such as CSF1R variants, may cause refractory ECD. We describe a patient with a novel somatic mutation in CSF1R ( CSF1R R549_E554delinsQ ) that resulted in refractory ECD affecting the central nervous system. Cell model studies, RNA sequencing analysis, and in silico protein modeling suggested that she had a gain‐of‐function mutation occurring in a region critical for autoinhibition. The patient was treated with pexidartinib, a CSF1R inhibitor, and has had a complete clinical and metabolic response lasting more than 1.5 years to date. To our knowledge, this is the first report to describe successful treatment of a patient with ECD by using an agent that specifically targets CSF1R. This case also highlights the critical role of individualized molecular profiling to identify novel therapeutic targets in ECD.
Abstract 20: Caridomoyocyte Biology Revealed by Fluorescence Ubiquitination-based Cell-cycle Indicators
Authors: Roberto Alvarez, Pearl J Quijada, Bingyan J Wang, Lilian Amheh, Natalie Navarrette, Maya Shaytrit, Thi Ho, Natalie A Gude, Mark A Sussman
Journal: Circulation Research (2017)

Existing myocyte contribution to new myocyte formation remains an active area of investigation. Novel experimental methodology is needed to faithfully label cardiomyocyte cell-cycle activity after birth and following injury. The Fluorescence Ubiquitination Cell Cycle Indicator (FUCCI) system can be used to aid visualization of cell cycle activity and progression by monitoring the inverse oscillation dynamics of fluorescently tagged cell cycle fusion proteins AzG-hGeminin and mKO2-hCdt1. Using this system, we hypothesize that cardiomyocytes retain the capacity to cycle throughout postnatal development and re-enter the cell cycle following acute myocardial infarction injury (MI). A novel cardiac specific FUCCI transgenic mouse model, αMHC-FUCCI, was developed to study cell-cycle dynamics of cardiomyocytes. αMHC-FUCCI hearts were collected throughout postnatal (PN) development to examine cardiomyocyte cell-cycle. Similarly, adult αMHC-FUCCI mice were subjected to MI, injected daily with BrdU and harvested at 3, 7, 10, 14 and 21 days post-MI for further analysis. Peak incidence of single mKO2-hCdt1 (7%, G 1 ) and AzG-hGem (2%, S/G 2 /M) fluorescence in cardiomyocytes occurs at PN7 and decreases over time as as confirmed by colocalization with BrdU and/or mitotic marker phospho-histone 3. Interestingly, continued mitotic activity exists at PN14 as observed by AzG+/pH3+ myocytes and concurrent mKO2+/AzG+ fluorescence is observed in 60% of adult myocardium by at one month. Together, these results indicate cardiac myocytes remain active at least two weeks after birth and transition into a G1/S phase as opposed to a mitotic exit (G0) as adults. Intriguingly, BrdU+ label is only detected in the non-myocyte interstitial population in and around the border zone through the first two weeks post-MI. BrdU+/AzG+ and or/mKO+ myocytes are detectable at 21days post-MI, indicating a lag in cardiomyocyte cell cycle re-entry. These results suggest myocytes retain the ability to re-enter the cell cycle at low levels three weeks post-MI. Future studies will analyze cardiomyocyte cell-cycle biology in response to diffuse injury and will further elucidate the mechanism behind myocardial regeneration.
Hypoxia-Inducible Factors in Cancer
Authors: Laura C. Kim, M. Celeste Simon
Journal: Cancer Research (2022)

Low oxygen concentrations (hypoxia) are detrimental to most species on Earth; thus, cells have evolved with adaptations allowing them to withstand transient hypoxia. As with other survival pathways, cancer cells have co-opted these mechanisms to keep up with the metabolic demands of rapid growth and proliferation in harsh tumor microenvironments. The most well-studied oxygen response pathway involves hypoxia-inducible factors (HIF) and their regulation by the von Hippel-Lindau protein (pVHL) and the prolyl hydroxylases (PHD1-3). This study from Zhong and colleagues, published in Cancer Research in 1999, was the first to show increased HIF1α expression in several cancer types and in metastases, suggesting a role for HIFs in disease progression. Since publication, significant progress has been made in the understanding of tumor hypoxia responses and efforts to target this pathway as a therapeutic strategy for patients with cancer are underway.See related article by Zhong and colleagues, Cancer Res 1999;59:5830-5.
AMA grams
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
JAMA Reference Directories
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Locally advanced esophageal cancer: Evaluation of prognosis by assessment of the “yp” stage based on the neoadjuvant regimen received.
Authors: Indika Gunadasa, Andrew Haydon, John Raymond Zalcberg, Yin Li Khu, Paul Burton, Wendy Brown
Journal: Journal of Clinical Oncology (2022)

356 Background: Neoadjuvant treatment in the form of chemoradiotherapy (nCRT) or chemotherapy (nCT) for resectable oesophageal cancer is the standard of care and improves R0 resection rates and overall survival (OS). The recently reported Neo-AEGIS study demonstrated ongoing equipoise between neoadjuvant chemoradiotherapy and peri-operative chemotherapy for oesophageal adenocarcinoma. There is limited data evaluating the prognostic outcomes by evaluation of the pathological stage after resection (yp stage) based on the neoadjuvant regimen received. The aim of this study was to look at the survival outcomes of patients with oesophageal cancer who received neoadjuvant therapy and to analyze the prognostic significance of pathological stage at surgery (“yp” stage) compared to the clinical stage based on the neoadjuvant therapy received. Methods: This was a single- centre, retrospective study over a fifteen-year period between 2005 and 2019. Consecutive patients with oesophageal and GOJ cancers that underwent resection post neoadjuvant treatment were included. The unit policy was to treat adenocarcinoma of the oesophagus and GOJ with perioperative chemotherapy until 2015 after which it was switched to neoadjuvant chemoradiotherapy in the form of the CROSS protocol. Results: Neoadjuvant treatment with either neoadjuvant chemoradiotherapy (nCRT) or neoadjuvant chemotherapy (nCT) prior to surgical resection was undertaken in 137 patients with resectable oesophageal and GOJ cancers between the years 2005 and 2019. The median age was 65 and 79% of the cohort was male. The majority of tumours were located in the lower oesophagus or GOJ and 96 patients in the cohort were clinical stage 3. 126 patients had adenocarcinoma and 11 patients had squamous cell carcinoma. 72 patients received nCT, and 65 patients received the nCRT. The “yp” stage showed 26 patients achieved a complete pathological response (CPR) and 47 patients were down-staged. The clinical stage was not a predictor of overall survival (p = 0.65). On the other hand, the “yp” stage was a significant predictor of survival (p &lt; 1×10 -8 ). In patients who received nCRT, 18 achieved a complete pathological response compared to 8 patients who had received nCT. Patients who received nCRT showed improved survival compared to patients who received nCT (p = 0.043). Patients who achieved a CPR with neoadjuvant chemotherapy had an OS of 100% compared to OS of 80% in patients who received nCRT (p = NS). Neoadjuvant chemoradiotherapy was associated with less loco-regional recurrences and distant recurrences compared to neoadjuvant chemotherapy. Conclusions: The “yp” stages, as well as down-staging with neoadjuvant therapy are strong predictors of survival. A greater proportion of patients achieved down-staging and CPR following neoadjuvant chemoradiotherapy compared to neoadjuvant chemotherapy.
HCV-RNA titers in the early course after orthotopic liver transplantation in patients with chronic hepatitis C T Fukumoto2, T Berg1, U Naumann2, V K�nig1, WO Bechstein2, P Lemmens2, H Keck2, P Neuhaus2, U Hoof1. Virchow-Hospital, Dept. of Internal Medicine1, Dept. of Surgery,2 Humboldt University, Berlin, Germany
Journal: Hepatology (1995)
Human Exposure to Mosquito-Control Pesticides—Mississippi, North Carolina, and Virginia, 2002 and 2003
Journal: JAMA (2005)

Public health officials weigh the risk for mosquito-borne diseases against the risk for human exposure to pesticides sprayed to control mosquitoes. Response to outbreaks of mosquito-borne diseases has focused on vector control through habitat reduction and application of pesticides that kill mosquito larvae. However, in certain situations, public health officials control adult mosquito populations by spraying ultra-low volume (ULV) (<3 fluid ounces per acre [oz/acre]) mosquito-control (MC) pesticides, such as naled, permethrin, and d-phenothrin. These ULV applications generate aerosols of fine droplets of pesticides that stay aloft and kill mosquitoes on contact while minimizing the risk for exposure to persons, wildlife, and the environment. This report summarizes the results of studies in Mississippi, North Carolina, and Virginia that assessed human exposure to ULV naled, permethrin, and d-phenothrin used in emergency, large-scale MC activities. The findings indicated ULV application in MC activities did not result in substantial pesticide exposure to humans; however, public health interventions should focus on the reduction of home and workplace exposure to pesticides.
Response to high‐dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients
Authors: Chul Won Choi, Byung Soo Kim, Jae Hong Seo, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim, Sang Kyun Sohn, Jae Seok Kim, Dong Gun Shin, Hun Mo Ryoo, Kyung Hee Lee, Je Jung Lee, Ik Joo Chung, Hyeoung Joon Kim, Jae Yong Kwak, Chang Yeol Yim, Jin Seok Ahn, Jung Ae Lee, Young Suk Park
Journal: American Journal of Hematology (2001)

This study was conducted to verify whether the response to high-dose intravenous immune globulin (IVIG) was related to the effect of splenectomy in chronic idiopathic thrombocytopenic purpura (ITP) patients. A total of 79 patients over 16 years of age were enrolled in this study. The response to the treatment was classified on the basis of the platelet count as no response (NR, <50 × 109/l), incomplete response (IR, (50–150) × 109/l), and complete response (CR, >150 × 109/l). The response was evaluated after the infusion of high-dose IVIG, within 2 weeks after splenectomy (immediate response), and during a follow-up period of more than 6 months after splenectomy (sustained response), respectively. 58 patients (73.4%) showed responses (CR or IR) to high-dose IVIG. After splenectomy, immediate responses were observed in 73 patients (92%). The response to high-dose IVIG had no relationship with the immediate response to splenectomy (P = 0.333). A follow-up evaluation was possible with 58 patients; 6 patients with NR in immediate responses did not show any response during the follow-up period, and 17 patients relapsed within 6 months after immediate responses, so 35 patients (60.3%) had sustained responses. Responders to IVIG had significantly higher sustained response rates to splenectomy than non-responders (62% vs. 38%, P = 0.001). These results indicate that the response to high-dose IVIG could be a valuable factor predicting the sustained response to splenectomy in chronic ITP patients. Am. J. Hematol. 66:197–202, 2001. © 2001 Wiley-Liss, Inc.
Correction: Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19
Authors: Alfred H.J. Kim, MD, PhD*, Jeffrey A. Sparks, MD, MMSc*, Jean W. Liew, MD, Michael S. Putman, MD, Francis Berenbaum, MD, PhD
Journal: Annals of Internal Medicine (2020)

Corrections16 June 2020Correction: Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19FREEThis correction concerns the following article:Ideas and OpinionsJun 2020A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19FREEAlfred H.J. Kim, MD, PhD*, Jeffrey A. Sparks, MD, MMSc*, Jean W. Liew, MD, Michael S. Putman, MD, Francis Berenbaum, MD, PhDAlfred H.J. Kim, MD, PhD*Washington University School of Medicine, St. Louis, Missouri (A.H.K.), Jeffrey A. Sparks, MD, MMSc*Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (J.A.S.), Jean W. Liew, MDUniversity of Washington, Seattle, Washington (J.W.L.), Michael S. Putman, MDNorthwestern Medicine, Chicago, Illinois (M.S.P.), Francis Berenbaum, MD, PhDSorbonne University, Inserm CRSA, AP-HP Saint-Antoine Hospital, Paris, France (F.B.)https://doi.org/10.7326/L20-0417 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In Kim and colleagues' article (1), Suleman Bhana, MD, FACR, was omitted from the Current Steering Committee. Suleman Bhana, MD, FACR, should have been included as part of the Current Steering Committee in front of Organizational Liaison and Media.This correction has been made to the online version.Reference1. Kim AHJ, Sparks JA, Liew JW, et al; COVID-19 Global Rheumatology Alliance. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med. 2020;172:819-21. [PMID: 32227189]. doi:10.7326/M20-1223 LinkGoogle Scholar Comments 0 Comments Sign In to Submit A Comment PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoA Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19 Alfred H.J. Kim , Jeffrey A. Sparks , Jean W. Liew , Michael S. Putman , Francis Berenbaum , Alí Duarte-García , Elizabeth R. Graef , Peter Korsten , Sebastian E. Sattui , Emily Sirotich , Manuel F. Ugarte-Gil , Kate Webb , and Rebecca Grainger , for the COVID-19 Global Rheumatology Alliance† Metrics 16 June 2020Volume 172, Issue 12 Page: 844 Keywords COVID-19 Hydroxychloroquine ePublished: 16 June 2020 Issue Published: 16 June 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Multifunctional elastomer cardiac patches for preventing left ventricle remodeling after myocardial infarction in vivo
Authors: Yuejun Yao, Aoqi Li, Shuqin Wang, Yuwen Lu, Jieqi Xie, Haolan Zhang, Deteng Zhang, Jie Ding, Zhaoyi Wang, Chenxi Tu, Liyin Shen, Lenan Zhuang, Yang Zhu, Changyou Gao
Journal: Biomaterials (2022)
Physical Activity Among Patients With Intracardiac Remote Monitoring Devices Before, During, and After COVID-19–Related Restrictions
Authors: Yuan Lu, Paul W. Jones, Karthik Murugiah, César Caraballo, Daisy S. Massey, Shiwani Mahajan, Rezwan Ahmed, Eric M. Bader, Harlan M. Krumholz
Journal: Journal of the American College of Cardiology (2022)
Weight and Blood Pressure
Authors: Rose Stamler
Journal: JAMA (1978)

In the nationwide Community Hypertension Evaluation Clinic screening of more than 1 million people, the group classifying itself as overweight had prevalence rates of hypertension 50% to 300% higher than other screenees. Frequency of hypertension in overweight persons aged 20 to 39 years was double that of normal weight and triple that of underweight persons. Among those aged 40 to 64 years, the overweight group had a 50% higher hypertension prevalence rate than the normal-weight group and 100% higher than the underweight group. With each higher degree of blood pressure elevation, relative frequency of hypertension with overweight was larger. Thus this study confirms, in the largest group surveyed to date, similar findings in previous cross-sectional surveys. It is also consistent with data from longitudinal and intervention studies on the importance of overweight in relation to hypertension. (<i>JAMA</i>240:1607-1610, 1978)
Misspelled Author Name in the Byline
Authors: Sheffali Gulati
Journal: JAMA Pediatrics (2021)

In the Editorial “Intrapartum Maternal Oxygen Supplementation—Friend or Foe?,”1 published online January 4, 2021, there was an error in the byline. The third author given as “Alireza A. Shamishirsaz, MD, ” should have appeared as “Alireza A. Shamshirsaz, MD.” This article has been corrected online.
Echocardiographic and Computed-tomographic Evaluation of the Fate of Bovine Pericardial Patch as a Pericardial Substitute in Bentall’s Procedure: Twenty-year’ Results
Authors: Ujjwal K. Chowdhury, Shikha Goja, Lakshmi Kumari Sankhyan, Niraj Nirmal Pandey, Sudheer Arava, Srikant Sharma, Abhinavsingh Chauhan, Vishwas Malik
Journal: Clinical Cardiology and Cardiovascular Interventions (2022)

Objective: The study was designed to ascertain the influence of usage of bovine pericardial patch in patients undergoing Bentall’s procedure with respect to reexploration for bleeding, mediastinal infection, avoidance of conduit adhesions, late development of pericardial constriction and calcification. Materials and Methods: We reviewed 150 patients (79 males) aged between 22 to 68 years (mean±SD 49.25±12.9 years) receiving a composite aortic conduit between January 1998 to December 2020 for annuloaortic ectasia (n=100), aortic dissection (n=49), and dilated aortic root in repaired tetralogy of Fallot (n=1). Twenty-five patients had Marfan’s syndrome. Modified “button technique” was performed by interposing a glutaraldehyde treated pericardial strip at the graft coronary anastomoses, and proximal aortic conduit suturing using interlocking interrupted, pledgeted mattress suture. On completion, the pericardial cavity was reconstructed using St. Jude Medical Biocor pericardial patch. To detect evidence of pericardial constriction, survivors underwent echocardiography and computed tomography. The Kaplan-Meier curve was drawn to show the probability of survival over a period of follow-up time. Results: Seven (4.7%) patients died of cardiac-related cause, 45% had transient hemodynamic instability, 55% had low cardiac output, and 87.1% had spontaneous return of sinus rhythm. The average 12-hour postoperative drainage was 245±70 ml and there was no mediastinal infection. At a mean follow-up of 172.4 (SD± 58.9) months, the actuarial survival was 94.2±0.04% (95% CI: 88.5-96.8), and there was no pericardial constriction or calcification. Conclusion: Reconstruction of pericardial cavity using Biocor bovine pericardial patch minimizes diffuse oozing of blood, graft infection, and is not associated with later development of pericardial constriction, or calcification.
Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials
Authors: Emmanuel Mignot, David Mayleben, Ingo Fietze, Damien Leger, Gary Zammit, Claudio L A Bassetti, Scott Pain, Dalma Seboek Kinter, Thomas Roth
Journal: The Lancet Neurology (2022)
Richard Lower, de Catarrhis 1672.
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intracoronary radiation therapy for patients with in-stent restenosis and chronic renal insufficiency Luis Gruberg, Ron Waksman, Roxana Mehran, Han-Soo Kim, Andrew E. Ajani, Lowell F. Satler, Augusto D. Pichard, Kenneth M. Kent, Alexandra J. Lansky. Washington Hospital Center, Washington, DC
Journal: Journal of the American College of Cardiology (2001)